Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Universal influenza virus vaccines and therapeutic antibodies</title><author><name sortKey="Nachbagauer, Raffael" sort="Nachbagauer, Raffael" uniqKey="Nachbagauer R" first="Raffael" last="Nachbagauer">Raffael Nachbagauer</name><affiliation><nlm:aff id="A1">Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA</nlm:aff></affiliation></author><author><name sortKey="Krammer, Florian" sort="Krammer, Florian" uniqKey="Krammer F" first="Florian" last="Krammer">Florian Krammer</name><affiliation><nlm:aff id="A1">Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">28216325</idno><idno type="pmc">5389886</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389886</idno><idno type="RBID">PMC:5389886</idno><idno type="doi">10.1016/j.cmi.2017.02.009</idno><date when="2017">2017</date><idno type="wicri:Area/Pmc/Corpus">000887</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000887</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Universal influenza virus vaccines and therapeutic antibodies</title><author><name sortKey="Nachbagauer, Raffael" sort="Nachbagauer, Raffael" uniqKey="Nachbagauer R" first="Raffael" last="Nachbagauer">Raffael Nachbagauer</name><affiliation><nlm:aff id="A1">Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA</nlm:aff></affiliation></author><author><name sortKey="Krammer, Florian" sort="Krammer, Florian" uniqKey="Krammer F" first="Florian" last="Krammer">Florian Krammer</name><affiliation><nlm:aff id="A1">Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA</nlm:aff></affiliation></author></analytic><series><title level="j">Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</title><idno type="ISSN">1198-743X</idno><idno type="eISSN">1469-0691</idno><imprint><date when="2017">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec id="S1"><title>Background</title><p id="P1">Current influenza virus vaccines are effective when well matched to the circulating strains. Unfortunately, antigenic drift and the high diversity of potential emerging zoonotic and pandemic viruses make it difficult to select the right strains for vaccine production. This problem causes vaccine mismatches which lead to sharp drops in vaccine effectiveness and long response times in case of novel pandemic viruses.</p></sec><sec id="S2"><title>Aims</title><p id="P2">To provide an overview of universal influenza virus vaccines and therapeutic antibodies in pre-clinical and clinical development.</p></sec><sec id="S3"><title>Sources</title><p id="P3">PubMed and <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link> were used as sources for this review.</p></sec><sec id="S4"><title>Content</title><p id="P4">Universal influenza virus vaccines that target conserved regions of the influenza virus including the hemagglutinin stalk domain, the ectodomain of the M2 ion channel or the internal matrix and nucleoproteins are in late pre-clinical and clinical development. These vaccines could confer broad protection against all influenza A and B viruses including drift variants and thereby abolish the need for annual re-formulation and re-administration of influenza virus vaccines. In addition, these novel vaccines would enhance our preparedness against emerging influenza virus pandemics. Finally, novel therapeutic antibodies against the same conserved targets are in clinical development and could become valuable tools in the fight against influenza virus infection.</p></sec><sec id="S5"><title>Implications</title><p id="P5">Both universal influenza virus vaccines and therapeutic antibodies are potential future options for the control of human influenza infections.</p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">9516420</journal-id><journal-id journal-id-type="pubmed-jr-id">21005</journal-id><journal-id journal-id-type="nlm-ta">Clin Microbiol Infect</journal-id><journal-id journal-id-type="iso-abbrev">Clin. Microbiol. Infect.</journal-id><journal-title-group><journal-title>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">1198-743X</issn><issn pub-type="epub">1469-0691</issn></journal-meta><article-meta><article-id pub-id-type="pmid">28216325</article-id><article-id pub-id-type="pmc">5389886</article-id><article-id pub-id-type="doi">10.1016/j.cmi.2017.02.009</article-id><article-id pub-id-type="manuscript">NIHMS857928</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Universal influenza virus vaccines and therapeutic antibodies</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nachbagauer</surname><given-names>Raffael</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Krammer</surname><given-names>Florian</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA</aff><author-notes><corresp id="FN1">To whom correspondence should be addressed: <email>Raffael.Nachbagauer@mssm.edu</email> or <email>Florian.krammer@mssm.edu</email></corresp><fn fn-type="COI-statement" id="FN3"><p><bold>Conflict of interest disclosure</bold></p><p>Dr. Krammer receives funding from National Institutes of Health, grants from PATH, the Bill and Melinda Gates Foundation and GlaxoSmithKline. In addition, the Icahn School of Medicine has filed several patents regarding influenza virus vaccines that list Drs. Krammer and Nachbagauer as co-authors.</p></fn></author-notes><pub-date pub-type="nihms-submitted"><day>17</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>12</day><month>2</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>4</month><year>2018</year></pub-date><volume>23</volume><issue>4</issue><fpage>222</fpage><lpage>228</lpage><pmc-comment>elocation-id from pubmed: 10.1016/j.cmi.2017.02.009</pmc-comment>
<abstract><sec id="S1"><title>Background</title><p id="P1">Current influenza virus vaccines are effective when well matched to the circulating strains. Unfortunately, antigenic drift and the high diversity of potential emerging zoonotic and pandemic viruses make it difficult to select the right strains for vaccine production. This problem causes vaccine mismatches which lead to sharp drops in vaccine effectiveness and long response times in case of novel pandemic viruses.</p></sec><sec id="S2"><title>Aims</title><p id="P2">To provide an overview of universal influenza virus vaccines and therapeutic antibodies in pre-clinical and clinical development.</p></sec><sec id="S3"><title>Sources</title><p id="P3">PubMed and <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link> were used as sources for this review.</p></sec><sec id="S4"><title>Content</title><p id="P4">Universal influenza virus vaccines that target conserved regions of the influenza virus including the hemagglutinin stalk domain, the ectodomain of the M2 ion channel or the internal matrix and nucleoproteins are in late pre-clinical and clinical development. These vaccines could confer broad protection against all influenza A and B viruses including drift variants and thereby abolish the need for annual re-formulation and re-administration of influenza virus vaccines. In addition, these novel vaccines would enhance our preparedness against emerging influenza virus pandemics. Finally, novel therapeutic antibodies against the same conserved targets are in clinical development and could become valuable tools in the fight against influenza virus infection.</p></sec><sec id="S5"><title>Implications</title><p id="P5">Both universal influenza virus vaccines and therapeutic antibodies are potential future options for the control of human influenza infections.</p></sec></abstract></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000887 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000887 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |